SCHEMBL5368730

SCHEMBL5368730

O=C1Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc2C1=Cc1ccc([N+](=O)[O-])s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 4/20 0.52
MGAT2 Q10469 2/20 0.49
MEN1 O00255 8/20 0.42
KMT2A Q03164 8/20 0.42
KDM4E B2RXH2 7/20 0.42
MAPT P10636 7/20 0.42
RECQL P46063 4/20 0.42
ATM Q13315 1/20 0.42
PDPK1 O15530 1/20 0.42
ALDH1A1 P00352 4/20 0.41
POLB P06746 3/20 0.41
BLM P54132 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
THRB P10828 3/20 0.40
HTT P42858 3/20 0.40
LMNA P02545 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
G6PD P11413 1/20 0.40
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365967 0.86 MOGAT2 (0.56) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5357966 0.86 MOGAT2 (0.54) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5362575 0.86 MOGAT2 (0.54) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5361437 0.85 MOGAT2 (0.51) MOGAT2MGAT2MEN1KMT2APDPK1
SCHEMBL5369910 0.84 MGAT2 (0.55) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5367898 0.83 MOGAT2 (0.56) MOGAT2MGAT2MAPTLMNA
SCHEMBL5358922 0.83 PDPK1 (0.63) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5363246 0.82 KDM4E (0.52) MEN1KMT2AKDM4EMAPTRECQL
SCHEMBL5363201 0.82 MOGAT2 (0.55) MOGAT2MGAT2MEN1KMT2AMAPT
SCHEMBL5358368 0.82 MOGAT2 (0.61) MOGAT2MGAT2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MGAT2 4714/4885MEN1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.